

Accula™

SARS-CoV-2 Test

Uses gold-standard RT-PCR test for detecting the SARS-CoV-2 virus that causes COVID-19 and provides results with high sensitivity and specificity in about 30 minutes.



COVID-19 Facts


40-45% OF COVID-19 CASES DO NOT LEAD TO SYMPTOMATIC DISEASE¹

UP TO 50% OF NEW INFECTIONS ORIGINATE FROM EXPOSURE TO INDIVIDUALS WITHOUT SYMPTOMS²



30 minutes for accurate, accessible, and actionable results

Collect sample



Elute sample



Load



Read



Features & Benefits

accurate

- Accurate results in about 30 minutes
- Highly sensitive and specific
100% positive and negative percent agreement (PPA and NPA) in prospective clinical study*
95.8% positive agreement and 100% negative percent agreement in a retrospective clinical study*
- 475 NDU/mL LoD for FDA SARS-CoV-2 Reference Panel

simple

- Easy to use
- 10-second start-up
- No instrument self-test, lot validation, or calibration

flexible

- Small footprint – palm-sized, portable device
- Easy storage – reagents stored at room temperature
- CLIA waived

*For more information, visit resources and support on thermofisher.com/mesa

Ordering Information

DESCRIPTION	CAT#	QTY	CPT CODE
RT-PCR Accula SARS-CoV-2 Test	COV4100	1 kit	87635QW
Accula system (dock)	D2000	1 dock	
Accula SARS-CoV-2 Control Kit	COV4100-1	each	

For more information, call 800-332-1042

THE AMERICAS

SEKISUI Diagnostics,
One Wall Street,
Burlington, MA 01803
Phone: 800 332 1042
Fax: 800 762 6311
Email: questions@sekisui-dx.com

INTERNATIONAL

SEKISUI Diagnostics (UK) Limited,
Liphook Way, Allington
Maidstone, Kent, ME16 0LQ, UK
Phone: +44 1622 607800
Fax: +44 1622 607801
Email: info@sekisui-dx.com

SEKISUI
DIAGNOSTICS

Because every result matters™

[sekisuidiagnostics.com](https://www.sekisuidiagnostics.com)

80-8715-00-00 08/21

References

1. Oran DP and Topol EJ (2020) Prevalence of Asymptomatic SARS-CoV-2 Infection. *Ann. Intern. Med.* doi:10.7326/M20-3012.
2. Johansson MA et al. (2021) SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. *JAMA Netw. Open* 4, e2035057–e2035057.

© 2021 Sekisui Diagnostics, LLC. All rights reserved. Because every result matters™ is a trademark of Sekisui Diagnostics, LLC. Accula™ is a trademark of Mesa Biotech, a Thermo Fisher Scientific Company. This test has not been FDA cleared or approved but has been authorized for emergency use by FDA for use by laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C. §263a, that meet requirements to perform high, moderate, or waived complexity tests. The test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. For Emergency Use Authorization (EUA) Only. For prescription use only. For in vitro diagnostic use.